Journal of Hematology & Oncology

Papers
(The H4-Index of Journal of Hematology & Oncology is 91. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity723
Targeting the Wnt/β-catenin signaling pathway in cancer699
Nanomaterials for cancer therapy: current progress and perspectives548
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19493
EZH2: a novel target for cancer treatment488
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer396
NK cell-based cancer immunotherapy: from basic biology to clinical development342
Next generation of immune checkpoint inhibitors and beyond328
Regulation of PD-L1 expression in the tumor microenvironment318
Roles of METTL3 in cancer: mechanisms and therapeutic targeting294
Challenges and advances in clinical applications of mesenchymal stromal cells284
Cancer vaccines as promising immuno-therapeutics: platforms and current progress268
RNA sequencing: new technologies and applications in cancer research266
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)249
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy246
Combination strategies to maximize the benefits of cancer immunotherapy243
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis236
Isolation and characterization of exosomes for cancer research231
Dendritic cell biology and its role in tumor immunotherapy225
Liquid biopsy: current technology and clinical applications225
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling222
Immunosenescence: a key player in cancer development220
Novel therapies emerging in oncology to target the TGF-β pathway217
Targeting mutant p53 for cancer therapy: direct and indirect strategies216
Applications of single-cell sequencing in cancer research: progress and perspectives214
Neutrophils in cancer carcinogenesis and metastasis212
Targeting hypoxic tumor microenvironment in pancreatic cancer211
Recent advances in therapeutic strategies for triple-negative breast cancer210
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells205
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research203
Recent advances in CAR-T cell engineering201
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response198
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions194
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)187
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy183
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma178
Targeting CD47 for cancer immunotherapy171
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation167
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019167
RNA-binding proteins in tumor progression166
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study159
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets159
Targeting MCL-1 in cancer: current status and perspectives159
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy155
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway153
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer153
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies150
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy147
MEK inhibitors for the treatment of non-small cell lung cancer146
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti144
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019144
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target144
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends139
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape139
Antibody–drug conjugates in solid tumors: a look into novel targets138
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update137
HMGB1 in inflammation and cancer134
Modeling neoplastic disease with spheroids and organoids133
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment133
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1131
Exploring immunotherapy in colorectal cancer130
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies129
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin125
Role of lysosomes in physiological activities, diseases, and therapy123
Mesenchymal stem/stromal cells in cancer therapy122
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential120
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies118
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy118
Targeting autophagy to overcome drug resistance: further developments117
The management of metastatic GIST: current standard and investigational therapeutics116
BCMA-targeted immunotherapy for multiple myeloma115
Emerging agents and regimens for AML113
Targeting Akt in cancer for precision therapy111
tRNA-derived RNA fragments in cancer: current status and future perspectives110
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies109
Gastric cancer treatment: recent progress and future perspectives107
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands105
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma102
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma102
Targeting EphA2 in cancer101
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation101
Emerging strategies to target RAS signaling in human cancer therapy100
The potential role of N7-methylguanosine (m7G) in cancer100
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts98
The long and short non-coding RNAs modulating EZH2 signaling in cancer98
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer96
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward96
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents96
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia96
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk94
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma92
0.18515801429749